MX370354B - Ligando de receptor de neurotensina. - Google Patents

Ligando de receptor de neurotensina.

Info

Publication number
MX370354B
MX370354B MX2015007193A MX2015007193A MX370354B MX 370354 B MX370354 B MX 370354B MX 2015007193 A MX2015007193 A MX 2015007193A MX 2015007193 A MX2015007193 A MX 2015007193A MX 370354 B MX370354 B MX 370354B
Authority
MX
Mexico
Prior art keywords
group
alkyl
hydrogen
carbon atoms
amino
Prior art date
Application number
MX2015007193A
Other languages
English (en)
Spanish (es)
Other versions
MX2015007193A (es
Inventor
Osterkamp Frank
Reineke Ulrich
Smerling Christiane
Haase Christian
Ungewiss Jan
Original Assignee
3B Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3B Pharmaceuticals Gmbh filed Critical 3B Pharmaceuticals Gmbh
Publication of MX2015007193A publication Critical patent/MX2015007193A/es
Publication of MX370354B publication Critical patent/MX370354B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2015007193A 2012-12-07 2013-12-06 Ligando de receptor de neurotensina. MX370354B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12008208.6A EP2740726A1 (en) 2012-12-07 2012-12-07 Neurotensin receptor ligands
PCT/EP2013/003700 WO2014086499A1 (en) 2012-12-07 2013-12-06 Neurotensin receptor ligands

Publications (2)

Publication Number Publication Date
MX2015007193A MX2015007193A (es) 2016-03-17
MX370354B true MX370354B (es) 2019-12-10

Family

ID=47355771

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007193A MX370354B (es) 2012-12-07 2013-12-06 Ligando de receptor de neurotensina.

Country Status (20)

Country Link
US (3) US10961199B2 (enExample)
EP (3) EP2740726A1 (enExample)
JP (2) JP6576828B2 (enExample)
KR (1) KR102290803B1 (enExample)
CN (2) CN109320502B (enExample)
AU (1) AU2013354422B2 (enExample)
BR (1) BR112015012530B1 (enExample)
CA (1) CA2893605C (enExample)
DK (2) DK3712131T3 (enExample)
ES (2) ES2941629T3 (enExample)
FI (1) FI3712131T3 (enExample)
HU (2) HUE050388T2 (enExample)
IL (1) IL239080B (enExample)
MX (1) MX370354B (enExample)
PL (2) PL3712131T3 (enExample)
PT (2) PT3712131T (enExample)
RU (1) RU2671970C2 (enExample)
SG (2) SG10201704564QA (enExample)
WO (1) WO2014086499A1 (enExample)
ZA (1) ZA201503446B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015273934B2 (en) * 2014-06-10 2020-08-20 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
EP2954934A1 (en) * 2014-06-11 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
EP2954933A1 (en) * 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
CN108473541B (zh) * 2015-11-24 2023-05-12 特拉斯福特普拉斯公司 通过受体介导的化学疗法治疗癌症的肽化合物和肽缀合物
EP3279197A1 (en) * 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
IL324632A (en) 2016-12-01 2026-01-01 Regeneron Pharma Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
CN110650974B (zh) 2017-02-10 2024-04-19 瑞泽恩制药公司 用于免疫-pet成像的放射性标记的抗-lag3抗体
MY197688A (en) 2017-07-24 2023-07-05 Regeneron Pharma Anti-cd8 antibodies and uses thereof
WO2021005125A1 (en) * 2019-07-08 2021-01-14 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
JP7750828B2 (ja) 2019-09-16 2025-10-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫pet撮像のための放射標識されたmet結合タンパク質
CN111875667B (zh) * 2020-07-16 2021-12-21 南方科技大学 有机金属螯合物及其制备方法与应用、探针
MX2023004715A (es) * 2020-10-22 2023-05-10 Nihon Mediphysics Co Ltd Metodo para producir un complejo de circonio radioactivo.
IL307632A (en) * 2021-04-23 2023-12-01 Fusion Pharmaceuticals Inc Cancer treatment methods
CA3220010A1 (en) * 2021-05-13 2022-11-17 The General Hospital Corporation Molecular probes for in vivo detection of aldehydes
EP4355377A4 (en) * 2021-06-16 2025-05-07 Fusion Pharmaceuticals Inc. COMBINATION COMPRISING A NEUROTENSIN RECEPTOR BINDING COMPOUND, GEMCITABINE AND NAB-PACLITAXEL
WO2022261770A1 (en) * 2021-06-16 2022-12-22 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound and folfirinox
WO2022266357A1 (en) * 2021-06-16 2022-12-22 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound and napox
CA3249925A1 (en) * 2022-01-28 2023-08-03 Fusion Pharmaceuticals Inc. Ntsr1-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy
IL314786A (en) * 2022-02-18 2024-10-01 Full Life Tech Hk Limited Compounds and radioligands for targeting neurotensin receptor and uses thereof
WO2023215778A1 (en) * 2022-05-03 2023-11-09 The University Of North Carolina At Chapel Hill Development of ntsr targeted agents for imaging and therapy applications
US12091454B2 (en) 2022-12-28 2024-09-17 Development Center For Biotechnology Humanized anti-human neurotensin receptor 1 antibodies and their uses
WO2025144920A1 (en) * 2023-12-28 2025-07-03 Radionetics Oncology, Inc. Neuropeptide y1 receptor (npy1r) targeted therapeutics and uses thereof
WO2025146126A1 (en) * 2024-01-04 2025-07-10 Full-Life Technologies Hk Limited Preparation method of compounds targeting neurotensin receptor

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110321A (en) 1976-07-12 1978-08-29 Folkers Karl Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity
US4425269A (en) 1982-06-07 1984-01-10 Merck & Co., Inc. Metabolically protected analogs of neurotensin
US4439359A (en) 1982-07-02 1984-03-27 Merck & Co., Inc. Cyclic octapeptide analogs of neurotensin
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
CA2086453A1 (en) 1992-12-30 1994-07-01 Mcgill University Marker for neurotensin receptor
US5407916A (en) 1993-02-16 1995-04-18 Warner-Lambert Company Neurotensin mimetics as central nervous system agents
FR2711140B1 (fr) * 1993-10-12 1996-01-05 Sanofi Sa 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
CA2183421A1 (en) 1994-02-18 1995-08-24 John Mertens Labelled peptide compounds
US6054557A (en) 1995-04-04 2000-04-25 Advanced Bioconcept (1994) Ltd. Fluorescent peptides
WO1996031531A2 (en) 1995-04-04 1996-10-10 Advanced Bioconcept, Inc. Fluorescent peptides
FR2732967B1 (fr) 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
WO1997004311A2 (en) 1995-07-20 1997-02-06 Advanced Bioconcept, Inc. Cell sorting with fluorescent peptides
DE69819478T2 (de) 1997-02-03 2004-09-02 Mallinckrodt, Inc. Verfahren zum Nachweis und zur Lokalisierung maligner menschlicher Pankreastumore
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
WO1999052539A1 (en) 1998-04-10 1999-10-21 Mayo Foundation For Medical Education And Research Neo-tryptophan
WO2000078796A2 (en) 1999-06-24 2000-12-28 Mallinckrodt Inc. Labeled neurotensin derivatives with improved resistance to enzymatic degradation
WO2005016141A1 (en) * 2003-07-09 2005-02-24 California Pacific Medical Center Remote detection of substance delivery to cells
US20060062729A1 (en) * 2004-09-09 2006-03-23 Carraway Robert E Enhanced ligand binding to neurotensin receptors
CA2676413A1 (en) * 2007-01-19 2008-07-31 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
EP2334642B1 (en) * 2008-09-16 2014-01-01 The Regents Of The University Of California Simplified one-pot synthesis of [18f]sfb for radiolabeling
MX2011005963A (es) 2008-12-05 2011-09-01 Angiochem Inc Conjugados de neurotensina o analogos de neurotensina y sus usos.
US8586043B2 (en) * 2009-01-07 2013-11-19 Inserm ( Institut National De La Sante Et De La Recherche Medicale) Methods for treating breast cancer with inhibitors of neurotensin activation of NTSR1
EP2454272B1 (en) 2009-07-16 2017-08-23 IASON GmbH Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors
WO2011156557A2 (en) * 2010-06-11 2011-12-15 Thomas James B Compounds active at the neurotensin receptor

Also Published As

Publication number Publication date
FI3712131T3 (fi) 2023-03-28
AU2013354422B2 (en) 2018-03-15
CN109320502A (zh) 2019-02-12
AU2013354422A1 (en) 2015-05-28
KR20150092300A (ko) 2015-08-12
CA2893605C (en) 2021-08-10
PL2928870T3 (pl) 2020-09-21
IL239080B (en) 2019-06-30
US20150299133A1 (en) 2015-10-22
ZA201503446B (en) 2016-01-27
CN104837819A (zh) 2015-08-12
US20210087149A1 (en) 2021-03-25
BR112015012530A2 (pt) 2017-09-12
JP7042776B2 (ja) 2022-03-28
JP6576828B2 (ja) 2019-09-18
EP3712131B1 (en) 2023-02-01
HK1210148A1 (en) 2016-04-15
EP2928870A1 (en) 2015-10-14
KR102290803B1 (ko) 2021-08-18
US20260078095A1 (en) 2026-03-19
RU2671970C2 (ru) 2018-11-08
MX2015007193A (es) 2016-03-17
WO2014086499A1 (en) 2014-06-12
SG10201704564QA (en) 2017-07-28
IL239080A0 (en) 2015-07-30
SG11201503880YA (en) 2015-06-29
PT3712131T (pt) 2023-04-04
ES2795923T3 (es) 2020-11-25
JP2019218375A (ja) 2019-12-26
PL3712131T3 (pl) 2023-05-02
US10961199B2 (en) 2021-03-30
HUE050388T2 (hu) 2020-11-30
BR112015012530B1 (pt) 2022-07-19
DK2928870T3 (da) 2020-07-13
JP2016501238A (ja) 2016-01-18
CN104837819B (zh) 2018-12-07
ES2941629T3 (es) 2023-05-24
EP2928870B1 (en) 2020-04-08
PT2928870T (pt) 2020-05-29
DK3712131T3 (da) 2023-03-20
RU2015127086A (ru) 2017-01-11
EP2740726A1 (en) 2014-06-11
CN104837819B9 (zh) 2019-07-09
CA2893605A1 (en) 2014-06-12
CN109320502B (zh) 2022-06-07
EP3712131A1 (en) 2020-09-23
HUE061839T2 (hu) 2023-08-28
WO2014086499A8 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
MX2015007193A (es) Ligando de receptor de neurotensina.
AR083069A1 (es) Analogos de nucleotidos sustituidos
BR112015009850A2 (pt) compostos de piridila substituídos por heteroarila úteis como moduladores de quinase
EA201791873A1 (ru) Полиморф ингибиторов syk
AR083831A1 (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
BRPI0818193B8 (pt) composto, composição farmacêutica, e, uso de um composto
AR098912A1 (es) Inhibidores de syk
WO2015188934A8 (en) Conjugate comprising a neurotensin receptor ligand and use thereof
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
BR112015018509A2 (pt) compostos de imidazo piridina
PE20191710A1 (es) Modulador del receptor de androgeno y usos de este
CO6220966A2 (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa
AR084553A1 (es) DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER
BR112012014807A2 (pt) "compostos adequados para o tratamento de sinucleopatias"
PE20151602A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
BR112016001979A2 (pt) composto de tetrazolinona e uso do mesmo
EA201290582A1 (ru) ЛИГАНДЫ НЕЙРОНАЛЬНОГО НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА αβ
IN2014DN07082A (enExample)
BR112015021386A2 (pt) moduladores de ácido biciclo [2.2.2] gpr120
BR112016000968A2 (pt) Processo para a preparação de bifenilanilidas halogenadas
BR112015029504A2 (pt) inibidores quinase
AR104262A1 (es) Derivados de cromeno como inhibidores de las fosfoinositido-3 quinasas
MX2013007938A (es) Compuesto biciclico novedoso o sal del mismo.
BR112013023480A8 (pt) composto heterocíclico saturado contendo nitrogênio

Legal Events

Date Code Title Description
FG Grant or registration